MMSI Merit Medical Systems Inc.

Merit Medical to Present at the 2024 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Congress

Merit Medical to Present at the 2024 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Congress

SOUTH JORDAN, Utah, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that clinicians will present updates on two of its pivotal studies during scientific sessions held on September 14 at CIRSE in Lisbon, Portugal.

Data will include 6-month clinical outcomes from the WAVE study, presented during the FIRST@CIRSE Clinical Trial session held between 11:30 and 12:30. An overview of the MOTION study design and methodology will be presented during the News on Stage session, “Meet the Brains Behind These Landmark Trials,” held between 13:00 and 14:00.

In addition to presenting at scientific sessions, Merit will sponsor two symposia. On September 15, from 11:30 to 12:30 in Auditorium 2, the satellite symposium will focus on current evidence and strategies for the clinical management of treating synovial arterial hypervascularity in the knee. On September 16, from 13:00 to 14:00 in Auditorium 7, the symposium will center on clinical evidence and treatment strategies to maintain long-term patency for patients undergoing hemodialysis.

“We are honored to attend CIRSE, connect with our physician partners, and all interventional radiologists who will attend the conference,” said Fred Lampropoulos, Merit’s Chairman and Chief Executive Officer.

Symposia can be viewed with a free myCIRSE account; no registration is required. On-demand access to sponsored sessions will be available within the first 24 hours after the live session is over and can be viewed with a free myCIRSE account; no registration is required. To create a myCIRSE account, visit

ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling more than 700 individuals. Merit employs approximately 7,100 people worldwide. 

TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.  

CONTACTS 

PR/Media Inquiries 

Sarah Comstock 

Merit Medical 

| 

INVESTOR INQUIRIES 

Mike Piccinino, CFA, IRC 

Westwicke - ICR 

| 



EN
11/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Merit Medical Systems Inc.

Merit Medical Systems Inc: 2 directors

Two Directors at Merit Medical Systems Inc sold after exercising options/sold 10,000 shares at between 105.000USD and 105.310USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trade...

 PRESS RELEASE

Merit Medical Reports Fourth Quarter and Full Year 2024 Results and Is...

Merit Medical Reports Fourth Quarter and Full Year 2024 Results and Issues Fiscal Year 2025 Guidance Fourth Quarter Highlights† Reported revenue of $355.2 million, up 9.4%Constant currency revenue* and constant currency revenue, organic* up 10.1% and up 6.1%, respectivelyGAAP operating margin of 10.3%, compared to 10.4% in prior year periodNon-GAAP operating margin* of 19.6%, compared to 16.6% in prior year periodGAAP EPS $0.46, down 2.6%,Non-GAAP EPS* $0.93, up 25.8%, andFree cash flow* generation of $65.3 million, up 18.4% Fiscal Year 2024 Highlights† Reported revenue...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Holding Above Prior Breakout Level Yet Again As discussed throughout the first half of January, we continue to believe that tariffs will mostly be used as a negotiation tactic, and much like Trump's prior presidency, will be much less impactful than feared. We reiterated this in yesterday's pre-market ETF Pathfinder, also noting "we anticipate the Canada/Mexico tariffs to be resolved relatively quickly, and therefore we view the latest pullback as a buying opportunity." Sure enough, bot...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Testing Prior Breakout Level DeepSeek appears to have turned the chatbot market upside-down, putting pressure on AI-linked stocks. While the dust has yet to settle, the good news is that the selloff has been largely contained to these AI-linked stocks. The rest of the market did not seem to care; the equal-weighted S&P 500 was roughly flat yesterday. Additionally, market dynamics remain healthy, with Treasury yields, the U.S. dollar (DXY), and WTI crude oil continuing to move lower, and...

 PRESS RELEASE

Merit Medical Announces Preliminary Unaudited Revenue for the Year End...

Merit Medical Announces Preliminary Unaudited Revenue for the Year Ended December 31, 2024 and Plans to Announce Fourth Quarter and Year End 2024 Results and Issue Fiscal Year 2025 Guidance on February 25, 2025 2024 preliminary unaudited revenue in the range of approximately $1.355 billion - $1.357 billion, up approximately 7.7% - 7.9% year-over-year2024 preliminary constant currency revenue* increased in the range of approximately 8.4% - 8.6% year over year2024 financial results and 2025 guidance to be released February 25, 2025 * Constant currency revenue is a non-GAAP financial measure....

ResearchPool Subscriptions

Get the most out of your insights

Get in touch